CYTK · CIK 0001061983
What Cytokinetics, Inc. told the SEC could break it.
Cytokinetics has no manufacturing of its own, so its disclosures converge on a fragile outsourced supply chain for its commercial product MYQORZO (aficamten). It relies on single-source contract manufacturers for the finished drug product, the active ingredient and the registered starting materials, plus a single-source CMO for EU blister packaging — and switching any of them would be slow and difficult. That chain reaches into China, where it sources key registered starting materials, which puts it directly in the path of a September 2025 proposal for up to 100% tariffs on imported pharmaceuticals (with uncertainty over whether those tariffs would reach APIs and starting materials). It also concentrates all of its facilities and critical records at a single South San Francisco headquarters near active earthquake zones.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- proposed up-to-100% tariffs on imported pharmaceuticalshigh
A September 2025 proposal for up to 100% tariffs on imported branded/patented pharmaceuticals — with uncertainty over whether it reaches imported starting materials and APIs — directly threatens Cytokinetics' China-sourced aficamten inputs.
“In September 2025, the United States administration announced plans to impose up to 100% tariffs on imported branded or patented pharmaceutical products, subject to certain exceptions.”
SEC filing →As of 2026
Sole-source dependency
- single-source CMOs for MYQORZO (drug product, API, starting materials, EU packaging)high
Cytokinetics has no manufacturing capabilities and relies on single-source CMOs for MYQORZO's finished drug product, active pharmaceutical ingredient and registered starting materials, plus a single-source CMO for EU blister packaging; switching CMOs would be slow and difficult.
“We currently rely on single source CMOs for the manufacture of any or all of MYQORZO as a finished drug product and the active pharmaceutical ingredient and registered starting materials used in the production of MYQORZO. We also rely on a single source CMO for the packaging of MYQORZO in blister packaging for use in Europe.”
SEC filing →As of 2026
Commodity & input dependence
- aficamten registered starting materials sourced from Chinamedium
Cytokinetics sources key registered starting materials for aficamten (MYQORZO) from manufacturers in China, exposing its sole commercial product to China trade disputes and restrictive legislation.
“we currently source key registered starting materials for aficamten from manufacturers in China.”
Geographic concentration
- single South San Francisco HQ near earthquake zonesmedium
All of Cytokinetics' facilities and critical records are concentrated at a single South San Francisco, California headquarters near active earthquake zones; a regional disaster could disrupt operations and destroy key R&D records.
“All our facilities and our important documents and records, such as hard and electronic copies of our laboratory books and records for our drug candidates and compounds and our electronic business records, are located in our corporate headquarters at a single location in South San Francisco, California near active earthquake zones.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Bayer AG
“we have committed to providing Sanofi and Bayer with supply of aficamten for development and commercialization of MYQORZO in China, Taiwan and Japan, which we will have to source from our contract manufacturers.”
Cited →“we have committed to providing Sanofi and Bayer with supply of aficamten for development and commercialization of MYQORZO in China, Taiwan and Japan, which we will have to source from our contract manufacturers.”
Cited →“Following the amendment in May 2024, the Cytokinetics Commercial Launch Funding is comprised of seven tranches with total funding of up to $ 525 million. Our return on the Cytokinetics Development Funding depends on the outcome of omecamtiv mecarbil's Phase 3 clinical trial and approval by the U.S. Food and Drug Administration (the “FDA”).”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch